从北京实验室到京津冀产业链：热景生物如何跑通研产用一体化路径

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. has established a successful model of "Beijing R&D, Hebei Production" to leverage regional advantages and enhance its production capacity in the field of in vitro diagnostics [1][2][3]. Group 1: Company Overview - Hotgen Biotech was founded in June 2005 and is headquartered in Daxing District, Beijing [1]. - The company focuses on innovative biotechnology solutions, including early disease screening, diagnosis, and treatment [1]. Group 2: Strategic Development - The company recognized the collaborative potential of Beijing, Tianjin, and Hebei around 2014-2015 and began exploring suitable locations for large-scale production [2]. - In 2016, Hotgen decided to establish a production base in Langfang, Hebei, to utilize the advantages of regional integration [2]. - The company has built a cross-regional collaboration system with R&D in Beijing and production in Hebei, enhancing efficiency in research and manufacturing [2][3]. Group 3: Financial and Operational Highlights - Hotgen's project for an annual production capacity of 12 million in vitro diagnostic reagents and 850 supporting instruments was funded with approximately RMB 287.82 million [2][3]. - Upon full production, the project is expected to generate annual revenue of approximately RMB 214.40 million and a net profit of about RMB 44.97 million, with an investment recovery period of 8.05 years [3]. - By 2024, the company anticipates achieving approximately RMB 511 million in revenue, primarily from in vitro diagnostic product sales [3]. Group 4: Product Development and Innovation - In December 2025, Hotgen received three medical device registration certificates, marking significant advancements in women's health, nutritional monitoring, and anemia management [4]. - The company is implementing a dual-driven strategy of "diagnostics + innovative drugs," focusing on antibody and nucleic acid drugs through partnerships with innovative pharmaceutical companies [5][6]. - Hotgen has established the "X-Gen AI New Drug Discovery and Design Research Center" to enhance drug development through advanced AI technologies [7].